Vor Bio to Participate in the JMP Securities Hematology and Oncology Summit

CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

JMP Securities Hematology and Oncology Summit
Fireside Chat: Tuesday, December 5, 2023 at 1:30 pm ET
Location: Virtual

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.41
+1.19 (0.51%)
AAPL  279.78
+0.93 (0.33%)
AMD  219.24
+1.71 (0.79%)
BAC  53.57
-0.08 (-0.15%)
GOOG  318.22
-1.90 (-0.59%)
META  643.61
-4.35 (-0.67%)
MSFT  489.08
-2.93 (-0.60%)
NVDA  180.04
+3.04 (1.72%)
ORCL  201.85
-0.10 (-0.05%)
TSLA  430.48
+0.31 (0.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.